MG
CYTK icon

Michael Gelband’s Cytokinetics CYTK Stock Holding History

Michael Gelband’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,000
Closed -$804K – 1559
2025
Q1 		$804K Buy
+20,000
New +$919K 0.01% 976
2024
Q2 		– Sell
-7,400
Closed -$520K – 1612
2024
Q1 		$520K Buy
+7,400
New +$572K ﹤0.01% 1128

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Michael Gelband's CYTK Position: Q2 2026 in Review

Michael Gelband increased its Cytokinetics (CYTK) stake by 377% in Q2 2026, buying an estimated $14.1M and bringing the position to 249,259 shares worth $21.2M. The position accounts for 0.14% of the portfolio, ranked #120.

Michael Gelband first reported a position in CYTK in Q4 2019 and has held it in 19 quarters since. The position peaked at $21.8M in Q4 2025. 479 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Michael Gelband held 249,259 shares of Cytokinetics worth $21.2M as of Q2 2026.
  • Michael Gelband bought 197,032 Cytokinetics shares in Q2 2026, an estimated $14.1M.
  • Cytokinetics made up 0.14% of Michael Gelband's portfolio in Q2 2026, its #120 holding.
  • Michael Gelband first reported a position in Cytokinetics in Q4 2019 and has held it in 19 quarters since.
  • Michael Gelband's Cytokinetics position peaked at $21.8M in Q4 2025.
  • 479 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.